Alzheimers therapeutics market Alzheimer’s Therapeutics Market By Molecule Type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E Pharmacies), By Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast up to 2025

Global Alzheimers Therapeutics Market Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[75 pages report] This market research report includes a detailed segmentation of the global Alzheimers Therapeutics market by molecule type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Others), by distribution channel (Hospital Pharmacies, Retail Pharmacies, and E Pharmacies), by region (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Alzheimers Therapeutics Market
Infoholics market research report predicts that the Global Alzheimers Therapeutics Market will grow at a CAGR of ~7.0% during the forecast period. The market has witnessed steady growth in the past few years and is sustaining due to an increase in geriatric population and promising pipeline in development.

Estimates are diverse, but specialists indicate that up to 5.5 million Americans aged 65 and above could have Alzheimers disease. Increase in geriatric population and promising pipeline in development is anticipated to boost the market growth. Emerging novel diagnostic technologies and investment in biomarkers for drug development are providing an opportunity for the development of the market. However, failures of late-stage drugs and restricted awareness about Alzheimers disease are hampering the market growth.
The majority of the revenue is generated from the leading players in the market with dominating sales of Eisai Co. Ltd, Novartis AG, Pfizer Inc., Eli Lilly & Company, Johnson & Johnson, Daiichi Sankyo Company Limited, F. Hoffmann-La Roche, H. Lundbeck A/S, TauRx Therapeutics Ltd, and Allergan.
According to the analysis, North America accounted for the largest share of the global Alzheimers therapeutics market in 2018. The Asia Pacific region is expected to witness the fastest growth rate due to the large patient pool and rising healthcare expenditure.
By Molecule Type:
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Others
In 2018, the largest share among the molecule types used for the treatment of Alzheimers disease are cholinesterase inhibitors. This may also improve signs of neuropsychiatry such as depression or agitation.
By End Users:
Hospital Pharmacies
Retail Pharmacies
E-Pharmacies
E-Pharmacies are increasingly adapted in many countries due to convenience and flexible accessibility.
By Regions:
North America
Europe
APAC
RoW
North America is dominant in the global Alzheimers therapeutics market in 2018. The significant share of the North American region comes from US which is due to the accessibility to good quality healthcare and good reimbursement facilities.
Alzheimers Therapeutics Market Research Competitive Analysis The Federal Government has led study initiatives on Alzheimers disease by the National Institute for Aging (NIA) at National Institutes for Health (NIH). Diverse variety of research is carried out through NIA-supported Alzheimer Research Centers across the US, which includes study of the causes, diagnosis and treatment, and management of the disease. NIA also supports the Alzheimer Clinical Trials Consortium which is intended to speed up and grow Alzheimer and associated dementia research and therapies. The NIH donated about $589 million in 2015 to AD study initiatives, which includes the Alzheimers Association, the National Health Institute (NIH), and the Federal Ministry of Health.
Key Vendors:
Eisai Co. Ltd.
Novartis AG
Pfizer Inc.
Eli Lilly & Company
Johnson & Johnson
Key Competitive Facts
Leading products like Aricept, Exelon, and Reminyl dominate the industry; Aricept with a cholinesterase inhibitor as its active component has the biggest business share in it.
There is an increase in combination therapy recommended to the patients with Alzheimers disease.
Benefits The report provides complete details about the sub-segments of the Alzheimers therapeutics market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, and government initiatives towards disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals and to analyze before investing or expanding the business in this market.
Key Takeaways:
Understanding the potential market opportunity with precise market size and forecast data.
A detailed market analysis focusing on the growth of Alzheimers therapeutics industry.
Factors influencing the growth of the Alzheimers therapeutics market.
In-depth competitive analysis of dominant and pure-play vendors.
Prediction analysis of the Alzheimers therapeutics market in both developed and developing regions.
Key insights related to major segments of the Alzheimers therapeutics market.
Latest market trend analysis impacting the buying behavior of consumers.
Key Stakeholders

1Industry Outlook
1.1Industry Overview
1.1.1Global Driver for Pharmaceutical Demand
1.1.2Pharmaceutical Spending Region Wise
1.1.3R&D Pipeline in Pharmaceutical Industry
1.1.4Top Pharma Drugs by Sales in 2017 ($Million)
1.2Total Addressable Market
2Report Outline
2.1Report Scope
2.2Report Summary
2.3Research Methodology
2.4Report Assumptions
3Market Snapshot
3.1Market Definition Infoholic Research3.2Segmented Addressable Market (SAM)
3.3Industry Trends
3.4Related Markets
3.4.1Parkinsons Disease
4Market Outlook
4.1Market Segmentation
4.2Porter 5 (Five) Forces
5Market Characteristics
5.1Market Dynamics
5.1.1Drivers
5.1.1.1Promising pipeline in development
5.1.1.2Increase in geriatric population
5.1.2Restraints
5.1.2.1Failures of late-stage drugs
5.1.2.2Restricted awareness about Alzheimers disease
5.1.3Opportunities
5.1.3.1Emerging novel diagnostic technologies
5.1.3.2Investment in biomarkers for drug development
5.1.4DRO Impact Analysis
5.2Key Stakeholders
6Molecule Type: Market Size and Analysis
6.1Overview
6.2Cholinesterase Inhibitors
6.3NMDA Receptor Antagonists
6.4Others
7Distribution Channel: Market Size and Analysis
7.1Overview
7.2Hospital Pharmacies
7.3Retail Pharmacies
7.4E Pharmacies
8Regions: Market Size and Analysis
8.1Overview
8.2North America
8.3Europe
8.4Asia Pacific
8.5Rest of the World
9Competitive Landscape
10Vendors Profile
10.1Novartis AG
10.2Eisai Co. Ltd.
10.3Pfizer Inc.
10.4Eli Lilly & Company
10.5Johnson & Johnson
11Companies to Watch for
11.1Daiichi Sankyo Company Ltd
11.2F. Hoffmann-La Roche
11.3H. Lundbeck A/S
11.4TauRx Therapeutics Ltd
11.5Allergan
Annexure
Abbreviations


List Of Tables




TABLE 1ALZHEIMERS THERAPEUTICS MARKET REVENUE, BY PRODUCT, 20182025 ($MILLION)
TABLE 2ALZHEIMERS THERAPEUTICS MARKET REVENUE, BY TYPE, 20182025 ($MILLION)
TABLE 3ALZHEIMERS THERAPEUTICS MARKET REVENUE, BY GEOGRAPHY, 20182025 ($MILLION)
TABLE 4BUSINESS SUMMARY: NOVARTIS AG
TABLE 5BUSINESS SUMMARY: EISAI CO. LTD
TABLE 6BUSINESS SUMMARY: PFIZER INC
TABLE 7BUSINESS SUMMARY: ELI LILLY & COMPANY
TABLE 8BUSINESS SUMMARY: JOHNSON & JOHNSON
TABLE 9BUSINESS SUMMARY: DAIICHI SANKYO COMPANY LTD
TABLE 10BUSINESS SUMMARY: F. HOFFMANN-LA ROCHE
TABLE 11BUSINESS SUMMARY: H. LUNDBECK A/S
TABLE 12BUSINESS SUMMARY: TAURX THERAPEUTICS LTD


List Of Figures

Charts

CHART 1GLOBAL PHARMACEUTICAL R&D SPENDING (20102016)
CHART 2ESTIMATED R&D INVESTMENT BY TOP 10 COMPANIES ($BN)
CHART 3RESEARCH METHODOLOGY OF GLOBAL ALZHEIMERS THERAPEUTICS MARKET
CHART 4GLOBAL ALZHEIMERS THERAPEUTICS MARKET REVENUE, 20182025 ($MILLION)
CHART 5GLOBAL ALZHEIMERS THERAPEUTICS MARKET SEGMENTATION
CHART 6PORTERS 5 FORCES ON GLOBAL ALZHEIMERS THERAPEUTICS MARKET
CHART 7PEST ANALYSIS OF GLOBAL ALZHEIMERS THERAPEUTICS MARKET
CHART 8MARKET DYNAMICS DRIVERS, RESTRAINTS & OPPORTUNITIES
CHART 9DRO - IMPACT ANALYSIS OF GLOBAL ALZHEIMERS THERAPEUTICS MARKET
CHART 10KEY STAKEHOLDERS OF GLOBAL ALZHEIMERS THERAPEUTICS MARKET
CHART 11GLOBAL ALZHEIMERS THERAPEUTICS MARKET REVENUE, BY PRODUCT, 2018 ($MILLION)
CHART 12CHOLINESTERASE INHIBITORS MARKET REVENUE, 20182025 ($MILLION)
CHART 13NMDA RECEPTOR ANTAGONISTS MARKET REVENUE, 20182025 ($MILLION)
CHART 14OTHERS MARKET REVENUE, 20182025 ($MILLION)
CHART 15GLOBAL ALZHEIMERS THERAPEUTICS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 20182025 ($MILLION)
CHART 16HOSPITAL PHARMACIES MARKET REVENUE, 20182025 ($MILLION)
CHART 17RETAIL PHARMACIES MARKET REVENUE, 20182025 ($MILLION)
CHART 18E PHARMACIES MARKET REVENUE, 20182025 ($MILLION)
CHART 19GLOBAL ALZHEIMERS THERAPEUTICS MARKET BY REGIONAL SEGMENTATION, 2018 (%)
CHART 20GLOBAL ALZHEIMERS THERAPEUTICS MARKET BY REGIONAL SEGMENTATION, 2025 (%)
CHART 21ALZHEIMERS THERAPEUTICS MARKET REVENUE IN NORTH AMERICA, 20182025 ($MILLION)
CHART 22ALZHEIMERS THERAPEUTICS MARKET REVENUE IN EUROPE, 20182025 ($MILLION)
CHART 23ALZHEIMERS THERAPEUTICS MARKET REVENUE IN ASIA PACIFIC, 20182025 ($MILLION)
CHART 24ALZHEIMERS THERAPEUTICS MARKET REVENUE IN REST OF THE WORLD, 20182025 ($MILLION)


Alzheimers Disease - Pipeline Review, H2 2019

Alzheimers Disease - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Alzheimers Disease - Pipeline Review, H2 2019, provides an overview of the Alzheimers Disease (Central Nervous System)

USD 2500 View Report

Alzheimers therapeutics market Alzheimer’s Therapeutics Market By Molecule Type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E Pharmacies), By Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast up to 2025

Global Alzheimers Therapeutics Market Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025[75 pages report] This market research report includes a detailed segmentation of the global Alzheimers Therapeutics market

USD 2750 View Report

alzheimers therapeutics market Alzheimer’s Therapeutics Market By Molecule Type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E Pharmacies), By Region (North America, Europe, Asia Pacific, and Rest of the World) – Global Forecast up to 2025

alzheimers therapeutics market Alzheimers Therapeutics Market By Molecule Type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E Pharmacies), By Region (North America, Europe, Asia Pacific, and Rest of the World) Global Forecast up to 2025 market research report available in single user pdf license with Aarkstore Enterprise at USD 2750

USD 2750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available